Concepedia

Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) – A phase II non-randomised trial

Emmanuel Mitry, Thomas Walter, Éric Baudin, Jean‐Emmanuel Kurtz, Philippe Ruszniewski, Sophie Dominguez-Tinajero, Leïla Bengrine-Lefèvre, Guillaume Cadiot, Clarisse Dromain, Françoise Farace,

European Journal of Cancer · 2014 · 109 citations · 30 references

DOI

Concepts

References

30

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 10.9K citations · Full text

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Anja Rinke, Hans‐Helge Müller, Carmen Schade‐Brittinger et al. · Journal of Clinical Oncology · 2009 · 2.5K citations

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Christopher G. Willett, Yves Boucher, Emmanuelle di Tomaso et al. · Nature Medicine · 2004 · 1.9K citations · Full text

, , +9

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Marianne Pavel, John D. Hainsworth, Éric Baudin et al. · The Lancet · 2011 · 1K citations

, , +8

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

James C. Yao, Catherine Lombard‐Bohas, Éric Baudin et al. · Journal of Clinical Oncology · 2009 · 648 citations · Full text

, , +15